A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

2024-516261-36-00 Protocol CX842A2104 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol CX842A2104

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 129
Countries 1
Sites 1

Erosive Gastroesophageal Reflux Disease (eGERD)

Key facts

Sponsor
Cinclus Pharma Holding AB (publ)
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Decision date (initial)
2024-08-16
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516261-36-00
EudraCT number
2022-001375-14
ClinicalTrials.gov
NCT05469854

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Erosive Gastroesophageal Reflux Disease (eGERD)

VersionLevelCodeTermSystem organ class
20.1 LLT 10017924 Gastroesophageal reflux 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cinclus Pharma Holding AB (publ)

Sponsor organisation
Cinclus Pharma Holding AB (publ)
Address
Kungsbron 1 Plan 3 Trappa G
City
Stockholm
Postcode
111 22
Country
Sweden

Scientific contact point

Organisation
Cinclus Pharma Holding AB (publ)
Contact name
Kajsa Larsson

Public contact point

Organisation
Cinclus Pharma Holding AB (publ)
Contact name
Kajsa Larsson

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Authorised, recruitment pending 129 1
Rest of world 0

Investigational sites

Sweden

1 site · Authorised, recruitment pending
CTC Clinical Trial Consultants AB
CTC Clinical Trial Consultants AB, Ingang 85 Vaning 2, 751 85, Uppsala

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-07 Sweden Acceptable with conditions
2024-08-16
2024-08-16
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-18 Sweden Acceptable
2025-01-16
2025-01-16
3 SUBSTANTIAL MODIFICATION SM-2 2025-04-09 Sweden Acceptable
2025-05-19
2025-05-26
4 SUBSTANTIAL MODIFICATION SM-3 2026-01-09 Sweden Acceptable
2026-03-13
2026-03-16